Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 279

1.

The risk we bear: the effects of review speed and industry user fees on new drug safety.

Olson MK.

J Health Econ. 2008 Mar;27(2):175-200. doi: 10.1016/j.jhealeco.2007.10.007. Epub 2007 Nov 29.

PMID:
18207263
2.

Managing delegation in the FDA: reducing delay in new-drug review.

Olson MK.

J Health Polit Policy Law. 2004 Jun;29(3):397-430.

PMID:
15328872
3.

Drug-review deadlines and safety problems.

Carpenter D, Zucker EJ, Avorn J.

N Engl J Med. 2008 Mar 27;358(13):1354-61. doi: 10.1056/NEJMsa0706341.

4.

FDA boxed warnings: how to prescribe drugs safely.

O'Connor NR.

Am Fam Physician. 2010 Feb 1;81(3):298-303. Review.

5.

Are novel drugs more risky for patients than less novel drugs?

Olson MK.

J Health Econ. 2004 Nov;23(6):1135-58.

PMID:
15556240
6.

Canadian and US drug approval times and safety considerations.

Rawson NS, Kaitin KI.

Ann Pharmacother. 2003 Oct;37(10):1403-8.

PMID:
14519031
7.
8.

FDA user fees and innovation.

Somberg J.

Am J Ther. 2008 Mar-Apr;15(2):97. doi: 10.1097/MJT.0b013e31816bf6f7. No abstract available.

PMID:
18356626
9.

The prescription Drug User Fee Act of 1992 and the new drug development process.

Kaitin KI.

Am J Ther. 1997 May-Jun;4(5-6):167-72.

PMID:
10423607
10.

FDA user fees approved.

[No authors listed]

Clin Pharm. 1993 Jan;12(1):3. No abstract available.

PMID:
8428431
11.

The FDA Drug Safety Bill: how safe are our drugs?

Cobert B.

Expert Opin Drug Saf. 2008 Jul;7(4):343-6. doi: 10.1517/14740338.7.4.343 .

PMID:
18613798
12.

New drug law to speed scientific review.

[No authors listed]

Nature. 1992 Oct 15;359(6396):563.

PMID:
1406977
13.
14.

Adverse drug reactions in elderly patients: alternative approaches to postmarket surveillance.

Noah BA, Brushwood DB.

J Health Law. 2000 Summer;33(3):383-454.

PMID:
11184355
15.

User fees for faster drug reviews. Are they helping or hurting the public health?

Thompson L.

FDA Consum. 2000 Sep-Oct;34(5):25-9. No abstract available.

16.
17.

FDA user fee may speed approval of Alzheimer's, Parkinson's drugs.

[No authors listed]

Geriatrics. 1992 Dec;47(12):15-6. No abstract available.

PMID:
1446840
18.
19.

Whatever happened to user fees and the FDA's promise to expedite new drug approvals?

Gatty B.

Hosp Formul. 1993 Jul;28(7):656, 655. No abstract available.

PMID:
10127048
20.

User-fee boost would up safety, reputations. A new paper suggests that drug makers, FDA can't afford not to raise user fees.

[No authors listed]

Med Health. 2005 Oct 31;59(39):2, 4. No abstract available.

PMID:
16279192

Supplemental Content

Support Center